Academic Journal
The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis
| العنوان: | The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis |
|---|---|
| المؤلفون: | Poynard, Thierry, Peta, Valentina, Munteanu, Mona, Charlotte, Frédéric, Ngo, Yen, Ngo, An, Perazzo, Hugo, Deckmyn, Olivier, Pais, Raluca, Mathurin, Philippe, Myers, Rob, Loomba, Rohit, Ratziu, Vlad |
| المساهمون: | CHU Pitié-Salpêtrière AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition CHU Pitié Salpêtrière (IHU ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière AP-HP, Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), BioPredictive Paris, Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Lille Inflammation Research International Center - U 995 (LIRIC), Institut Pasteur de Lille, Pasteur Network (Réseau International des Instituts Pasteur)-Pasteur Network (Réseau International des Instituts Pasteur)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Gilead Sciences, Inc. Foster City, CA, USA, Department of Medicine Univ California San Diego (MED - UC San Diego), School of Medicine Univ California San Diego (UC San Diego), University of California San Diego (UC San Diego), University of California (UC)-University of California (UC)-University of California San Diego (UC San Diego), University of California (UC)-University of California (UC), University of California (UC), The research leading to these results has received funding from the European Community’s Seventh Framework Program (FP7/2007–2013) under grant agreement HEALTHF2–2009–241762 for the project FLIP., The FLIP partners’ consortium Vlad Ratziu, Thierry Poynard: Assistance Publique Hopitaux de Paris, Groupe Hospitalier Pitie Salpetriere, Sorbonne University, Paris, France, Jean-Marie Castille, Yen Ngo: Biopredictive SAS, Paris, France, Tania Langon: Alma Consulting Group SAS,Paris, France, Chris Day, Dina Tiniakos: University of Newcastle, Newcastle, UK, Debbie Lawlor: University of Bristol, Bristol, UK, Giulio Marchesini: Universita di Bologna, Bologna, Italy, Fabio Marra: University di Firenze, Firenze, Italy, Elisabetta Bugianesi: Universita degli studi di Torino, Torino, Italy, Stefano Bellentani: Universita di Modena e Reggio Emilia, Modena, Italy, Jean-Francois Dufour: Universit_ e de Berne, Berne, Switzerland, Manuel Romero Gomez: Servicio Andaluz de Salud, Spain, Thorkild Sørensen: Bispebjerg hospital, Region Hovedstaden, Bispebjerg, Dutch, Claudio Tribelli: Fondazione Italiana Fegato-Fonlus, Milano, Italy, Samuele De Minicis: Universita di Ancona, Ancona,Italy, Michael Trauner: Medizinischen Universitaet, Wien, Austria, Claudia Oliveira: University of S~ ao Paulo School of Medicine, S~ ao Paulo, Brazil. The FLIP pathology consortium Pierre Bedossa: Assistance Publique-Hopitaux de Paris, hopital Beaujon, University Paris- Diderot, Paris, France, Alastair D. Burt: School of Medicine, University of Adelaide Adelaide, Australia, Annette S.H. Gouw: Department of Pathology & Medical Biology, University Medical Center Groningen, Groningen, The Netherlands, Carolin Lackner: Institute of Pathology, Medical University of Graz, Graz, Austria, Peter Schirmacher: Institut Fur Pathologie, Universit€ atsklinikum Heidelberg, Heidelberg, Germany, Luigi Terracciano: Institute of Pathology, University Hospital, Basel, Switzerland, DinaTiniakos: Medical School, National and Kapodistrian University of Athens, Greece and Medical School, Newcastle University, Newcastle-upon-Tyne, UK, J. Brain: Medical School, Newcastle University, Newcastle-upon-Tyne, UK, Yvonne Bury: Royal Victoria Infi rmary, Hospitals Foundation Trust, Newcastle upon Tyne, UK, Daniela Cabibi: University of Palermo, Palermo, Italy, Frederic Charlotte: Assistance Publique Hopitaux de Paris, Groupe Hospitalier Pitie- Salpetriere, Universite university of Torino, Ospedale Molinette, Torino, Italy, Luisa Losi: Modena University Hospital, Modena, Italy, Matteo Montani: Institute of Pathology, University of Bern, Bern, Switzerland, Marı a Jesus Pareja: Hospital Universitario de Valme, Sevilla, Spain, Dominique Wendum: Assistance Publique-Hopitaux de Paris, Hopital St Antoine Sorbonne University, Fritz Wrba: Medical University of Vienna, Vienna, Austria, Marianne Ziol: Assistance Publique-Hôpitaux de Paris, Hopital Jean Verdier, Universite Paris 13, Bobigny, France, Vlad Ratziu: Assistance Publique Hopitaux de Paris, Hopital Pitie Salpetriere, Sorbonne University, Paris,France. The FibroFrance group Thierry Poynard, Vlad Ratziu, Dominique Thabut, Joseph Moussalli, Pascal Lebray, Marika Rudler, Francoise Imbert Bismuth, Frederic Charlotte, Olivier Rosmorduc, Yvon Calmus: Anti- Fibrosis Center, Assistance Publique Hopitaux de Paris, Groupe Hospitalier Pitie-Salpetriere, Sorbonne University, Paris, France, Agnes Hartemann, Sophie Jacqueminet: Diabetes Center, Assistance Publique Hopitaux de Paris, Groupe Hospitalier Pitie-Salpetriere, Sorbonne University, Paris, France, Eric Bruckert, Philippe Giral: Lipid Center, Assistance Publique Hopitaux de Paris, Groupe Hospitalier Pitie-Salpetriere, Sorbonne University, Paris, France, Sylvie Naveau, Gabriel Perlemuter: Alcoholic liver Disease Center, Assistance Publique Hopitaux de Paris, Antoine Beclere Hospital, Clamart, France, Brigitte Varsat: Prevention Centers of Caisse Primaire Assurance Maladie, Paris, France, Anne Mercadier: Transfusion Unit, Assistance Publique Hopitaux de Paris, Groupe Hospitalier Pitie-Salpetriere, Sorbonne University, Paris, France Selonsertib group Study investigators in United States: Manal Abdelmalek, Hays Arnold, Kiran Bambha, Jaideep Behari, Stephen Caldwell, Naga Chalasani, Michael Charlton, James Cooper, Bradley Freilich, Reem Ghalib, Bilal Hameed, Kris V. Kowdley, Michelle Lai, Eric Lawitz, Rohit Loomba, Parvez Mantry, Mary Rinella, Arun Sanyal, Mitchell L. Shiffman, Paul Thuluvath, and Dawn Torres, in Canada : Saumya Jayakumar, and Magdy Elkhashab., European Project: 241762,EC:FP7:HEALTH,FP7-HEALTH-2009-single-stage,FLIP(2010) |
| المصدر: | ISSN: 0954-691X. |
| بيانات النشر: | CCSD Lippincott, Williams & Wilkins |
| سنة النشر: | 2019 |
| المجموعة: | LillOA (HAL Lille Open Archive, Université de Lille) |
| مصطلحات موضوعية: | [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology |
| الوصف: | International audience ; BACKGROUND:Serum biomarkers of steatosis such as the SteatoTest are recommended for large-scale screening studies, because imaging is less accessible and more expensive.AIMS: The primary aim of this retrospective analysis of prospective studies was to construct a new SteatoTest-2 that was not inferior to the reference first-generation SteatoTest, but that did not include BMI or bilirubin, as these two components can increase test variability because of the assessment of weight and height and in case of Gilbert syndrome or hemolysis, respectively.PATIENTS AND METHODS: Five different subsets of 2997 patients with biopsies were evaluated for test construction and validation, and four to assess the prevalence of steatosis in target populations with increasing risks of steatosis. The performance of the SteatoTest-2 was compared with the reference test, using the noninferiority test (0.10 margin) and the Lin concordance coefficient.RESULTS: Areas under the receiver operating characteristic curve of the SteatoTest-2 were noninferior to the reference test (P<0.001). Areas under the receiver operating characteristic curve varied in the SteatoTest-2 and the reference test according to subsets and the prevalence of steatosis, with 0.772 [95% confidence interval (CI): 0.713-0.820] versus 0.786 (95% CI: 0.729-0.832) in the 2997 cases with biopsy and 0.822 (95% CI: 0.810-0.834) versus 0.868 (95% CI: 0.858-0.878) in the 5776 cases including healthy individuals without risk factors of steatosis as controls, respectively. The Lin coefficient was highly concordant (P<0.001), from 0.74 (95% CI: 0.74-0.74) in presumed NAFLD to 0.91 (95% CI: 0.89-0.93) in the construction subset.CONCLUSION: The SteatoTest-2 is simpler and noninferior to the first-generation SteatoTest for the diagnosis of steatosis, without the limitations of BMI and bilirubin. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| Relation: | info:eu-repo/semantics/altIdentifier/pmid/30516570; info:eu-repo/grantAgreement/EC/FP7/241762/EU/Fatty liver: Inhibition of Progression/FLIP; PUBMED: 30516570 |
| DOI: | 10.1097/MEG.0000000000001304 |
| الاتاحة: | https://hal.sorbonne-universite.fr/hal-02274944 https://hal.sorbonne-universite.fr/hal-02274944v1/document https://hal.sorbonne-universite.fr/hal-02274944v1/file/document.pdf https://doi.org/10.1097/MEG.0000000000001304 |
| Rights: | info:eu-repo/semantics/OpenAccess |
| رقم الانضمام: | edsbas.C8A0ED21 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1097/MEG.0000000000001304 |
|---|